GlassScriptPhysician profile
Julia Tjandera
NPI 1568056828
$4,937.80
in general payments reported to CMS, 2019-2025
33 companies · $2,310 in 2025
The $2,310 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $532 · 2024: $2,096 · 2025: $2,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,905 · Education: $32.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.30 |
| Education | $32.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.57 | 2023-2025 | |
| Pfizer INC. | $625.65 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $599.93 | 2023-2025 | Xtampza, Belbuca |
| Ucb, INC. | $391.28 | 2024-2025 | Zilbrysq, Nayzilam, Briviact |
| Lundbeck LLC | $298.54 | 2024-2025 | Vyepti |
| Csl Behring | $253.92 | 2023-2025 | Hizentra |
| Eisai INC. | $229.09 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $228.41 | 2023-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $219.46 | 2023-2025 | Ajovy |
| Amgen INC. | $211.84 | 2024-2025 | Uplizna |
| Neurelis, INC. | $207.29 | 2023-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $109.95 | 2023-2025 | Nuplazid |
| Lilly USA, LLC | $90.63 | 2023-2025 | Kisunla, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.21 | 2024-2025 | Relistor |
| Sk Life Science, INC. | $84.07 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $74.08 | 2023-2025 | Ongentys, Ingrezza |
| Grifols USA, LLC | $70.55 | 2023-2024 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $67.39 | 2023-2025 | Ztlido |
| Nevro Corp. | $61.28 | 2024 | Senza |
| Globus Medical, INC. | $52.94 | 2025 | Senza |
| Merz Pharmaceuticals, LLC | $39.09 | 2024 | Inbrija, Xeomin |
| Averitas Pharma INC. | $35.88 | 2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $34.78 | 2025 | Hyqvia |
| Almatica Pharma LLC | $33.30 | 2023 | Gralise |
| Axsome Therapeutics, INC. | $27.40 | 2025 | Symbravo |
| Tonix Medicines, INC. | $26.20 | 2025 | Tonmya |
| Amneal Pharmaceuticals LLC | $20.22 | 2025 | Crexont |
| Genzyme Corporation | $17.74 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.42 | 2023 | Nuedexta |
| Vertex Pharmaceuticals Incorporated | $17.20 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $16.80 | 2024 | Zilretta, Iovera |
| Boston Scientific Corporation | $16.31 | 2025 | General - Dbs |
| Genentech USA, INC. | $14.38 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Tjandera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.